Literature DB >> 27425854

Genomic characterization of recurrent high-grade astroblastoma.

Tejus A Bale1, Malak Abedalthagafi2, Wenya Linda Bi3, Yun Jee Kang4, Parker Merrill1, Ian F Dunn3, Adrian Dubuc1, Sarah K Charbonneau4, Loreal Brown4, Azra H Ligon1, Shakti H Ramkissoon5, Keith L Ligon6.   

Abstract

Astroblastomas are rare primary brain tumors, diagnosed based on histologic features. Not currently assigned a WHO grade, they typically display indolent behavior, with occasional variants taking a more aggressive course. We characterized the immunohistochemical characteristics, copy number (high-resolution array comparative genomic hybridization, OncoCopy) and mutational profile (targeted next-generation exome sequencing, OncoPanel) of a cohort of seven biopsies from four patients to identify recurrent genomic events that may help distinguish astroblastomas from other more common high-grade gliomas. We found that tumor histology was variable across patients and between primary and recurrent tumor samples. No common molecular features were identified among the four tumors. Mutations commonly observed in astrocytic tumors (IDH1/2, TP53, ATRX, and PTEN) or ependymoma were not identified. However one case with rapid clinical progression displayed mutations more commonly associated with GBM (NF1(N1054H/K63)*, PIK3CA(R38H) and ERG(A403T)). Conversely, another case, originally classified as glioblastoma with nine-year survival before recurrence, lacked a GBM mutational profile. Other mutations frequently seen in lower grade gliomas (BCOR, BCORL1, ERBB3, MYB, ATM) were also present in several tumors. Copy number changes were variable across tumors. Our findings indicate that astroblastomas have variable growth patterns and morphologic features, posing significant challenges to accurate classification in the absence of diagnostically specific copy number alterations and molecular features. Their histopathologic overlap with glioblastoma will likely confound the observation of long-term GBM "survivors". Further genomic profiling is needed to determine whether these tumors represent a distinct entity and to guide management strategies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Astroblastoma; GBM; NGS; SETD2; aCGH

Mesh:

Year:  2016        PMID: 27425854     DOI: 10.1016/j.cancergen.2016.06.002

Source DB:  PubMed          Journal:  Cancer Genet


  9 in total

1.  Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.

Authors:  William Boisseau; Philipp Euskirchen; Karima Mokhtari; Caroline Dehais; Mehdi Touat; Khê Hoang-Xuan; Marc Sanson; Laurent Capelle; Aurélien Nouet; Carine Karachi; Franck Bielle; Justine Guégan; Yannick Marie; Nadine Martin-Duverneuil; Luc Taillandier; Audrey Rousseau; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Oncologist       Date:  2019-07-25

2.  Patterns of care and survival outcomes in patients with astroblastoma: an individual patient data analysis of 152 cases.

Authors:  Supriya Mallick; Rony Benson; Bhanuprasad Venkatesulu; Wineeta Melgandi; Goura K Rath
Journal:  Childs Nerv Syst       Date:  2017-05-05       Impact factor: 1.475

3.  Multimodal molecular analysis of astroblastoma enables reclassification of most cases into more specific molecular entities.

Authors:  Matthew D Wood; Tarik Tihan; Arie Perry; Geeta Chacko; Clinton Turner; Cunfeng Pu; Christopher Payne; Alexander Yu; Serguei I Bannykh; David A Solomon
Journal:  Brain Pathol       Date:  2017-10-27       Impact factor: 6.508

4.  AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.

Authors:  Ryan D Chow; Christopher D Guzman; Guangchuan Wang; Florian Schmidt; Mark W Youngblood; Lupeng Ye; Youssef Errami; Matthew B Dong; Michael A Martinez; Sensen Zhang; Paul Renauer; Kaya Bilguvar; Murat Gunel; Phillip A Sharp; Feng Zhang; Randall J Platt; Sidi Chen
Journal:  Nat Neurosci       Date:  2017-08-14       Impact factor: 24.884

5.  Astroblastoma in a Young Female Patient: A Case Report and Literature Review of Clinicopathological, Radiological and Prognostic Characteristics and Current Treatment Strategies.

Authors:  Muhammad Sadiq; Iftikhar Ahmad; Jamila Shuja; Zubair Ahmad; Riyasat Ahmed; Khushnaseeb Ahmad
Journal:  Brain Tumor Res Treat       Date:  2017-10-31

Review 6.  BCOR involvement in cancer.

Authors:  Annalisa Astolfi; Michele Fiore; Fraia Melchionda; Valentina Indio; Salvatore N Bertuccio; Andrea Pession
Journal:  Epigenomics       Date:  2019-05-31       Impact factor: 4.778

7.  Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis.

Authors:  Norman L Lehman; Aisulu Usubalieva; Tong Lin; Sariah J Allen; Quynh T Tran; Bret C Mobley; Roger E McLendon; Matthew J Schniederjan; Maria-Magdalena Georgescu; Marta Couce; Mohanpal S Dulai; Jack M Raisanen; Mousa Al Abbadi; Cheryl A Palmer; Eyas M Hattab; Brent A Orr
Journal:  Acta Neuropathol Commun       Date:  2019-03-15       Impact factor: 7.801

8.  Cerebral astroblastoma with oligodendroglial-like cells: A case report.

Authors:  Jian Gu; Yihua Wang; Juanhan Yu
Journal:  Medicine (Baltimore)       Date:  2021-10-29       Impact factor: 1.889

9.  Malignant Astroblastoma

Authors:  Binnaz Sarper; Büşra Yaprak Bayrak; Hatice Halis; Burcu Alparslan; Hülya Yeni Bayraktar
Journal:  Balkan Med J       Date:  2020-03-26       Impact factor: 2.021

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.